NCT04505540 - Start Treatment and Recovery for Opioid Use Disorder | Crick

Overview

The purpose of this study is 1) to evaluate whether emergency department-initiated medically assisted treatment with Buprenorphine/Naloxone in patients presenting with opioid use disorder will produce positive outcomes at 1 week, 3 months and 6 months after treatment initiation.

The emergency department is a critical missed opportunity to engage patients with opioid use disorder in medication-assisted treatment, the most effective current treatment for the disorder. Patients presenting at the emergency department with opioid use disorder will be given the opportunity to immediately start medication assisted treatment with Naloxone/Buprenorphine then referred either to a specialized addiction bridge clinic or a local waivered provider for further treatment.

Study Type

INTERVENTIONAL

Allocation

NA

Purpose

SUPPORTIVE_CARE

Masking

NONE

Enrollment

104

Conditions

Opioid-use Disorder Mental Disorder Opioid Medication Assisted Treatment

Interventions

Bridge ClinicOTHER

Specialized addiction bridge clinic

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patient at Emergency Department * Diagnosis opioid use disorder according to criteria Diagnostic and Statistical Manual (DSM) 5 Exclusion Criteria: * Participating in alternate treatment program for opioid use disorder * Prisoner * Inability to communicate * Psychosis * Suicidality * History of Buprenorphine injection * Critical Illness

Locations (1)

University of Vermont Medical Center

Burlington, Vermont, United States

Outcomes

Primary Outcomes

Number of Participants With Self-reported Treatment Retention

Self-reported enrollment in treatment for opioid use disorder after 1 week

Time frame: 1 week

Number of Participants With Self-reported Treatment Retention

Self-reported enrollment in treatment for opioid use disorder after 3 months

Time frame: 3 months

Number of Participants With Self-reported Treatment Retention

Self-reported enrollment in treatment for opioid use disorder after 6 months

Time frame: 6 months

Secondary Outcomes

Number of Participants With Illicit Opioid Use

Urine analyzed for opioids (buprenorphine, methadone, oxycodone, hydrocodone, hydromorphone, heroin, fentanyl) and other drugs (cocaine, amphetamines, benzodiazepines, cannabinoids) via enzyme multiplied immunoassay. Note buprenorphine and methadone positive results not treated as illicit.

Time frame: 1 week

Number of Participants With Illicit Opioid Use

Urine analyzed for opioids (buprenorphine, methadone, oxycodone, hydrocodone, hydromorphone, heroin, fentanyl) and other drugs (cocaine, amphetamines, benzodiazepines, cannabinoids) via enzyme multiplied immunoassay. Note buprenorphine and methadone positive results not treated as illicit.

Time frame: 3 months

Number of Participants With Illicit Opioid Use

Urine analyzed for opioids (buprenorphine, methadone, oxycodone, hydrocodone, hydromorphone, heroin, fentanyl) and other drugs (cocaine, amphetamines, benzodiazepines, cannabinoids) via enzyme multiplied immunoassay. Note buprenorphine and methadone positive results not treated as illicit.